open access
Evaluation of neutrophil HDL-C ratio — a new inflammation marker in non-alcoholic fatty liver disease
, 2
Affiliations- Department of Gastroenterology, Medova Hospital, Konya, Türkiye
- Department of Endocrinology, Konya City Hospital, Konya, Türkiye
open access
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a global disease estimated to affect one-third of the world’s population. NAFLD is the hepatic manifestation of metabolic syndrome. In recent years, formulations have been made using haematological laboratory parameters, and it has been reported to be associated with inflammation and fibrosis in the liver. In this study, we aimed to evaluate the neutrophil to high-density lipoprotein (HDL) cholesterol (HDL-C) ratio (NHR) in patients diagnosed with NAFLD by ultrasonographic imaging for the first time in the literature.
Material and methods: The study was carried out by recruiting men and women between the ages of 18 and 65 years who applied to the check-up outpatient clinic of our hospital. Ultrasonography was used as the diagnostic method for hepatosteatosis in all cases. Venous blood samples were taken from the patients for haematological and biochemical measurements.
Results: The study population consisted of 155 patients, 115 of whom were fatty liver patients and 40 were controls. NHR was determined as 99.6 ± 56.8 in those with grade 1 fatty liver, 114.98 ± 39.2 in those with grade 2, 122.9 ± 51.1 in those with grade 3, and 86.17 ± 35.2 in the control group. In the analysis, NHR was statistically significantly higher in grade 2 and 3 fatty liver patients compared with the control group (p = 0.03 and 0.01, respectively). However, there was no statistical difference between grade 1 fatty liver patients and the control group (p = 0.53).
Conclusions: We found higher NHR in patients with NAFLD. NHR is a cheap and easy to access parameter. An elevated NHR with FIB-4 in patients with NAFLD may be a marker of liver inflammation or fibrosis.
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a global disease estimated to affect one-third of the world’s population. NAFLD is the hepatic manifestation of metabolic syndrome. In recent years, formulations have been made using haematological laboratory parameters, and it has been reported to be associated with inflammation and fibrosis in the liver. In this study, we aimed to evaluate the neutrophil to high-density lipoprotein (HDL) cholesterol (HDL-C) ratio (NHR) in patients diagnosed with NAFLD by ultrasonographic imaging for the first time in the literature.
Material and methods: The study was carried out by recruiting men and women between the ages of 18 and 65 years who applied to the check-up outpatient clinic of our hospital. Ultrasonography was used as the diagnostic method for hepatosteatosis in all cases. Venous blood samples were taken from the patients for haematological and biochemical measurements.
Results: The study population consisted of 155 patients, 115 of whom were fatty liver patients and 40 were controls. NHR was determined as 99.6 ± 56.8 in those with grade 1 fatty liver, 114.98 ± 39.2 in those with grade 2, 122.9 ± 51.1 in those with grade 3, and 86.17 ± 35.2 in the control group. In the analysis, NHR was statistically significantly higher in grade 2 and 3 fatty liver patients compared with the control group (p = 0.03 and 0.01, respectively). However, there was no statistical difference between grade 1 fatty liver patients and the control group (p = 0.53).
Conclusions: We found higher NHR in patients with NAFLD. NHR is a cheap and easy to access parameter. An elevated NHR with FIB-4 in patients with NAFLD may be a marker of liver inflammation or fibrosis.
Keywords
NAFLD; NHR; FIB-4
About this articleTitle
Evaluation of neutrophil HDL-C ratio — a new inflammation marker in non-alcoholic fatty liver disease
Journal
Issue
Article type
Original paper
Published online
2023-10-31
Page views
543
Article views/downloads
177
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(6).
Keywords
NAFLD
NHR
FIB-4
Authors
Enver Avcı
Mine Ozturk
References (29)- Hardy T, Oakley F, Anstee QM, et al. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum. Annu Rev Pathol. 2016; 11: 451–496.
- Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2011; 5(2): 189–200.
- Younossi Z, Anstee Q, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1): 11–20.
- Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2): 389–97.e10.
- Lee J, Vali Y, Boursier J, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021; 41(2): 261–270.
- Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007; 46(1): 32–36.
- McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59(9): 1265–1269.
- Kahraman NK, Kahraman C, Kocak FE, et al. Predictive value of neutrophil to lymphocyte ratio in the severity of non-alcoholic fatty liver disease among type 2 diabetes patients. Acta Gastro-Enterologica Belgica, Vol. Acta Gastroenterol Belg. 2016 ; 79(3): 295–300.
- Aktas G, Duman TT, Kurtkulagi Ö, et al. Liver Steatosis is Associated Both with Platelet Distrubition Width, Neuthrophil/Lymphocyte and Monocyte/Lymphocyte Ratios. Prim Health Care. 2020; 10(4): 001–004.
- Huang JB, Chen YS, Ji HY, et al. Neutrophil to high-density lipoprotein ratio has a superior prognostic value in elderly patients with acute myocardial infarction: a comparison study. Lipids Health Dis. 2020; 19(1): 59.
- Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412–419.
- Deprince A, Haas JT, Staels B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease. Mol Metab. 2020; 42: 101092.
- Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011; 332(6037): 1519–1523.
- Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010; 52(5): 1836–1846.
- Takaki A, Kawai D, Yamamoto K. Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH). Int J Mol Sci. 2013; 14(10): 20704–20728.
- Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cell Mol Immunol. 2022; 19(2): 177–191.
- Xu R, Huang H, Zhang Z, et al. The role of neutrophils in the development of liver diseases. Cell Mol Immunol. 2014; 11(3): 224–231.
- Kou T, Luo H, Yin L. Relationship between neutrophils to HDL-C ratio and severity of coronary stenosis. BMC Cardiovasc Disord. 2021; 21(1): 127.
- Curcic S, Holzer M, Frei R, et al. Neutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL. Biochim Biophys Acta. 2015; 1851(2): 184–193.
- Başyiğit F, Çöteli C. Relationship between the neutrophil to HDL-C ratio and anatomical significance of coronary artery stenosis in patients with documented myocardial ischemia. Eur Rev Med Pharmacol Sci. 2022; 26(9): 3179–3184.
- Ozgeyik M, Ozgeyik MO. Long-term Prognosis after Treatment of Total Occluded Coronary Artery is well Predicted by Neutrophil to High-Density Lipoprotein Ratio: a Comparison Study. Kardiologiia. 2021; 61(7): 60–67.
- Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 2018; 17(1): 122.
- Bril F, Sninsky JJ, Baca AM, et al. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD. J Clin Endocrinol Metab. 2016; 101(2): 644–652.
- Haas JT, Vonghia L, Mogilenko DA, et al. Transcriptional Network Analysis Implicates Altered Hepatic Immune Function in NASH development and resolution. Nat Metab. 2019; 1(6): 604–614.
- Gehrke N, Schattenberg JM. Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? Gastroenterology. 2020; 158(7): 1929–1947.e6.
- Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 Index Can Independently Predict Major Adverse Cardiovascular Events in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2022; 117(3): 453–461.
- Yan Z, Liu Y, Li W, et al. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis. Eur J Clin Invest. 2022; 52(11): e13855.
- Jin JL, Zhang HW, Cao YX, et al. Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease. Hepatol Int. 2021; 15(2): 413–423.
- Bulló M, García-Lorda P, Megias I, et al. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res. 2003; 11(4): 525–531.
